Search results

You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years¹

Galderma delivers net sales of 4.765 B USD in the first nine months, up 25.1% at constant currency year-on-year, and raises full-year net sales guidance

Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, October 22, 2026 – Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Represents second approved indication for Restylane Defyne in U.S.

Expands Galderma Aesthetics’ growing Restylane product portfolio

Galderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full year

Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, July 23, 2026 – Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026.

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

DALLAS, Texas, October 3, 2022 /PRNewswire/ -- Galderma announced today its continued partnership with National Breast Cancer Foundation Inc. (NBCF), one of the leading breast cancer organizations in the world.

What are you looking for?

Galderma Global

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma delivers net sales of 4.765 B USD in the first nine months, up 25.1% at constant currency year-on-year, and raises full-year net sales guidance

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Galderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full year

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma delivers net sales of 4.765 B USD in the first nine months, up 25.1% at constant currency year-on-year, and raises full-year net sales guidance

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Galderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full year

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

Confirm navigation